UK Markets close in 15 mins

PharmaEssentia Corporation (6446.TWO)

Taipei Exchange - Taipei Exchange Delayed price. Currency in TWD
Add to watchlist
564.00-9.00 (-1.57%)
At close: 01:30PM CST

PharmaEssentia Corporation

No. 3, Park Street
2nd & 13th Floors Nangang District
Taipei 115
Taiwan
886 2 2655 7688
https://www.pharmaessentia.com

Sector(s)Healthcare
IndustryDrug Manufacturers—Specialty & Generic
Full-time employees

Key executives

NameTitlePayExercisedYear born
Dr. Ching-Leou Teng Ph.D.Chairman & Chief Pharmaceutical OfficerN/AN/AN/A
Mr. Ko-Chung Lin Ph.D.Founder, CEO, Chief Strategy Officer & DirectorN/AN/AN/A
Mr. Chan-Kou HwangPres, GM & DirectorN/AN/AN/A
Ms. Snow ChangAccounting Mang. & Sr. Mang. of Fin.N/AN/AN/A
Mr. Samuel LinVP and Head of Bus. Operations & StrategyN/AN/AN/A
Mr. Roddy McilwainSr. VP and Head of Sales & MarketingN/AN/AN/A
Ms. Anjana PursnaniSr. VP & Head of PeopleN/AN/AN/A
Dr. Albert Qin M.D., Ph.D.Chief Medical OfficerN/AN/AN/A
Narihisa MiyachiHead of Japan Medical AffairsN/AN/AN/A
Mr. Yen-Tung LuanChief Operating Officer of Taichung PlantN/AN/AN/A
Amounts are as of , and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in TWD.

Description

PharmaEssentia Corporation engages in the research, development, production, and sale of therapeutic products for the treatment of human diseases in Taiwan and internationally. Its products include BESREMi (ropeginterferon alfa-2b) that is used for the treatment of chronic myelogenous leukemia, chronic neutrophilic leukemia, primary myelofibrosis, polycythemia vera, essential thrombocythemia, and hepatitis B and C; and Anti-PD-1 antibody for the treatment of liver cancer. The company also licensed to develop Oraxol for the treatment of breast, gastric, gastro-esophageal, and esophageal cancer; and KX01 for the treatment of psoriasis and actinic keratosis. It also focuses on the drug research and development programs in the areas of hematology, infectious disease, oncology, and dermatology. PharmaEssentia Corporation was founded in 1990 and is headquartered in Taipei, Taiwan.

Corporate governance

PharmaEssentia Corporation’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.